High-Affinity PD-1 Protein Has Potential.
A small, engineered protein that selectively binds to PD-L1 with very high affinity was more effective in shrinking tumors in preclinical studies than existing antibody-based immune checkpoint inhibitors, and it may overcome some the drawbacks of these agents, according to data presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.